Dr. David Samadi, a celebrity doctor, is now deemed a master of robotic oncology. As the chairman of urology at Lenox Hill Hospital in New York, Dr. Samadi is trusted with some of the most challenging cases in urology and surgical procedures for urology. As the Chief of Robotic Surgery at Lenox Hill Hospital, Dr. Samadi often performs laparoscopic surgeries, believed to be the best option for a less invasive approach. Because he is an expert in open traditional surgery and laparoscopic, he is now an expert in robotic prostate surgery. What has led to his appointment as the best surgeon to pick for prostate cancer, is his dedication to research on early detection of cancer. His astounding follow-up has also made him a favorite, dedicated to choosing a treatment path immediately following, as well as his careful treatment.
All of these aspects of his expertise have made him a highly regarded option in his field. During the life of his career, Dr.Samadi has also won numerous awards and recognition for his practice of medicine. The New York Magazine voted him the best doctor in 2009, 2010, 2011, 2012, and 2015. He was also awarded as the most compassionate doctor in 2010. 2011 .and in 2013. One of his most prestigious recognitions yet, was for the vote for him to be named among America’s Top Doctors for Cancer during the years of 2009, 2010, 2011, 2012, and 2013. Dr. Samadi has been awarded many times for various aspects of his career, but winning the Patient’s Choice Award is what makes him the most proud. He proudly claimed this award in 2008, 2009, 2010, 2011, and in 2013.
There are many reasons that people choose to seek out the expertise of Dr. Samadi, but those who are celebrities or in high pressure industries know that he’ll get to the root of their diagnosis as quickly as possible. As a board certified uro-oncologist and surgeon, he is highly sought after for helping people get through the process quickly. Arming his patients with as much information as possible has aided his patients in their ability to have successful outcomes.As a urologist, Dr. Samadi works with patients in all aspects of urology including kidney and bladder diseases and cancer, as well as minimally invasive treatments. He is of Persian-Jewish descent, and came to America in the late 80’s.
Working in a healthcare industry to save lives is a rewarding career. Working in the cancer industry requires dedicated health professionals in a variety of professions. There are medical or clinical professionals and the non-clinical professionals. If you want to work in the healthcare industry but not necessarily in direct contact with patients, then there are many non-clinical healthcare jobs from which to choose a promising career of helping people. Over 100 non-clinical career jobs are available at the Cancer Treatment Center of America like those below.One such non-clinical healthcare job is a ‘quality improvement coordinator (QI-RN).’ A QI-RN coordinates with the cancer team in administrative tasks involved in managing a healthcare facility. A QI is responsible for managing each cancer patient’s quality of care records. A QI requires a bachelor or master’s degree and an RN license. A Cancer Information Specialist (‘CIS’) is responsible for educating patients and their loved ones on how to manage and prevent illnesses through healthy eating habits.
A CIS is a clinical educator who teaches people about nutrition and how they can plan and keep a dietary system based on the patient’s medical needs. A CIS is also responsible for creating and marketing educational materials to patients and the public. A bachelor or master’s degree in health education is required.A ‘program analyst’ is the IT expert of a hospital or a healthcare facility. They collect healthcare data from the medical staff and enters it in a database. A program analyst oversees the efficacy and data evaluation of an organization’s computer functions. They analyze statistical data to present reports that may be called for by the medical team. Many program analysts have degrees in IT systems, but they also carry a degree in business management. A ‘healthcare risk management manager’ oversees all healthcare procedures to make sure that a hospital or healthcare facility is not subject to malpractice.
They oversee all health policies to minimize any liabilities or legal contingencies. This positionworks with the medical staff to ensure that patient care is in compliance with state and federal regulations. A healthcare risk manager requires a bachelor or master’s degree in nursing.The Cancer Treatment Centers of America (‘CTCA’) began in 1988 as a small for-profit medical venture. Today, they have a network of 5 hospitals throughout the U.S. They specialize in an integrated approach which means that each patient is assigned a dedicated team of doctors and medical specialists/clinicians that provide cancer patients with a personalized treatment plan.CTCA also has a special program called patient empowered care which gives better care and comfort in a unique environment. CTCA has a better remission success rate than any other U.S. medical facility. The Cancer Treatment Centers of America also boasts of an A to Z care system which means they take care of air and lodging arrangements to travel to their facilities, they help with the insurance paperwork, and more.
When battling cancer, one should be able to focus on their physical and mental health without worrying about the cost to their finances. While the rising cost of healthcare has been a concern for years in the United States, researchers at Oncotarget have shown that this is especially troubling for cancer patients. While the correlation between affordable medication prices and a country’s wealth appear to be directly correlated, there is one country that remains an outlier: the United States. Oncotarget researchers have shown that the US actually has the highest average patented drug prices in the entire world. Some patients are finding themselves taking drastic measures such as going on “medical vacations” to destinations such as India where the treatments for cancer and other diseases are usually a fraction of the cost they are in the US. Learn more about Oncotarget at Eurekalert.org.
In an economy where companies like Oncotarget are engaging international markets in hopes for cures, who determines the prices and how they should be set? Should the countries with the best infrastructure shoulder the costs to allow access in countries with less opportunities or should the prices remain consistent across the board especially if the research made took place internationally?
At 2017’s Frontiers in Cancer Science, Oncotarget awarded four grants to international researchers to sponsor them in their travels. Hosted by 7 different research institutions, Frontiers in Cancer Research took place in Singapore on November 6-8th. This event brings some of the tops researchers and experts in the field of cancer science together to exchange ideas and information freely without the burden of distance. Follow Oncotarget on Linkedin.
Oncotarget’s grants were awarded to researchers presenting on a range of topics such as the impact of renal cancer medications to mesothelioma’s resistance to chemotherapy and the effects of asbestos in this process. With the aid of Oncotarget’s travel grants, these researchers may be able to find treatments affordable to all… without a “medical vacation”.
Clay Siegall received his doctorate in Genetics from George Washington University and a Bachelor of Science degree in Zoology from the University of Maryland. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, Chief Executive Officer, and Chairman of the Board of Directors. During the company’s establishment, cancer treatments were controlled by chemotherapy that could barely distinguish between killing cancer cells and normal cells. Clay wanted to improve the lives of people living with cancer through the development of targeted therapies to cater for unmet needs.
Clay Sieagall established Seattle Genetics on a scientific innovation basis along with meticulous research, drug development practice, and his zeal to assist others. Under his leadership, the company, Seattle Genetics, was able to build a diverse pipeline of antibody cancer therapies which include ADCETRIS (brentuximab vedotin) for cancer treatment. ADCETRIS is currently an international brand approved in over 65 nations.
Clay Siegall is also in charge of the Seattle Genetics capital-raising activities having secured over $675 million through private and public funding, in addition to the company’s first public offering in 2001. Clay Siegall previously served at the Bristol-Myers Squibb Pharmaceutical Research Institute for a six year period and prior to that, he worked with the National Cancer Institute, National Institutes of Health from 1988 to 1991. Clay is also a member of the Board of Directors of a private biotechnology firm-Alder Biopharmaceuticals. Clay Siegall is an author and has published over 70 books and also holds 15 patents.
Clay Siegall has led Seattle Genetics into multiple strategic licenses for the company’s ADC technology which include AbbVie, Genentech (Roche), Astellas, Pfizer, and GlaxoSmithKline which have collectively generated more than $350 million to this day. There are more than 20 ADCs in the clinical development that utilize the company’s technology across internal and partner programs. Clay says that an important component their business plan involves partnering with other industry leaders and innovators in oncology drug development. He adds that the company’s ADC collaborations have helped market their technology, allowing the company to place resources into new ideas and new approaches to help patients.